Clinical trial
Effect of Ruboxistaurin on Clinically Significant Macular Edema
NCT00133952 · Chromaderm, Inc., Industry · Completed
Key facts
| NCT number | NCT00133952 |
|---|---|
| Title | Effect of Ruboxistaurin on Clinically Significant Macular Edema |
| Official title | The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema |
| Lead sponsor | Chromaderm, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Macular Edema |
| Intervention type | Drug |
| Interventions | Ruboxistaurin, Placebo |
| Enrollment | 309 |
| Start date | Aug 1, 2005 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Aug 24, 2005 |
| Last update posted | Oct 6, 2016 |
| Countries | Canada, Denmark, Germany, Lithuania, Mexico, Portugal, Romania, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: